Mylan, Pfizer settle patent suit on generic Detrol LA

Fri Sep 7, 2012 5:35pm IST

Stocks

   

(Reuters) - Mylan Inc said it settled with Pfizer Inc a lawsuit that accused it of infringing patents on overactive bladder drug Detrol LA.

Mylan can start selling its generic versions of Pfizer's drug from January 1, 2014, or earlier under some limited circumstances, but not after March 1, 2014, if the U.S. Food and Drug Administration approves.

Terms of the settlement are subject to review by the Federal Trade Commission and the U.S. Department of Justice, and other details are confidential, Mylan said.

The settlement with Mylan comes days after Pfizer resolved a similar dispute with Impax Laboratories Inc late last month.

(Reporting by Zeba Siddiqui in Bangalore; Editing by Akshay Lodaya)

INTERNAL SECURITY

REUTERS SHOWCASE

Setback For Sahara

Setback For Sahara

Supreme Court defers verdict on Sahara plea to raise more debt on hotels  Full Article 

SpiceJet Crisis

SpiceJet Crisis

SpiceJet says fleet grounded on lack of fuel  Full Article 

Drug Patents

Drug Patents

Novartis sues Cipla over respiratory drug Onbrez   Full Article 

Boost for Tata Steel

Boost for Tata Steel

Tata Steel restarts key iron mines amid shortage  Full Article 

Reuters Poll

Reuters Poll

BSE Sensex to hit 32,980 by December 2015  Full Article 

India Outlook

India Outlook

ADB trims growth forecasts for developing Asia, says India to grow 5.5 pct in 2014  Full Article 

Real Estate

Real Estate

HDFC to raise $500 mln real estate private equity fund - sources  Full Article 

Banking Sector

Banking Sector

Japan banks to bulk up India presence on improving ties   Full Article 

U.S. Spending Bill

U.S. Spending Bill

Obama signs bill $1.1 trillion government spending bill  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage